Clinical Trial Update: XL999 Administered Intravenously to a Subject With Advanced Malignancies

View source ↗

Summary

XL999 was administered intravenously to a subject with advanced malignancies; the trial entry is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• XL999

Snippet

Sponsor: John Sarantopoulos | Conditions: Advanced Malignancy | Status: NO_LONGER_AVAILABLE